These results indicate that the combination of TOE and PD-1/PD-L1 inhibitor 2 not only enhances the antitumor effects of PD-1/PD-L1 inhibitor 2 therapy but also limits immune escape by tumors and improves the tumor microenvironment, thereby increasing the overall efficacy of cancer treatment. The gene discussed is PDCD1; the disease is cancer.